Şunu aradınız:: bronchopulmonary (İngilizce - Maltaca)

bronchopulmonary dysplasia
bpd

bronchopulmonary dysplasia common:
displażja bronkopulmonari komuni:

breathing problems (bronchopulmonary dysplasia),
problemi biex tieħu n-nifs (displasija bronkopulmonarja),

table 1 undesirable effects in prophylactic clinical studies with premature and bronchopulmonary dysplasia paediatric populations
tabella 1 effetti mhux mixtieqa fi studji kliniċi profilattiċi fuq gruppi ta ’ pazjenti pedjatriċi prematuri u pazjenti pedjatriċi li jbatu minn displażja bronkopulmonari

children less than 2 years of age and requiring treatment for bronchopulmonary dysplasia within the last 6 months.
tfal ta’ taħt is-sentejn fl-eta’, li tul l-aħħar 6 xhur kellhom bżonn il-kura għal displażja bronkopulmonari.

xolair has not been studied in patients with hyperimmunoglobulin e syndrome or allergic bronchopulmonary aspergillosis or for the prevention of anaphylactic reactions, including those provoked by food allergy.
xolair ma kienx studjat f’ pazjenti li jsofru b’ sindrome ta ’ iperimmunoglobulina e jew asperġillożi bronkopulmonari allerġika jew għall- użu preventiv ta ’ reazzjonijiet anafilattiċi, inklużi dawk li jkunu kawżati minn allerġija ta 'l- ikel.

the indication was reworded to state ciprofloxacin's utility in gram negative bacterial infections of the lower respiratory track causing exacerbations of chronic obstructive pulmonary disease, bronchopulmonary infections in cystic fibrosis or in bronchiectasis and pneumonia.
l- indikazzjoni nkitbet mill- ġdid biex tistqarr l- utilità ta ’ ciprofloxacin f’ infezzjonijiet batteriċi gram negattivi fil- parti t’ isfel tal- passaġġi respiratorji li jikkaġunaw taħrixiet ta ’ mard kroniku pulmonari okklussiv, infezzjonijiet bronkopulmonari f’ fibrożi ċistika jew fi bronkjektażi u pulmonite.

in a clinical curative trial involving 175 preterm newborn infants less than 35 weeks of gestational age, the incidence of bronchopulmonary dysplasia at 36 weeks post-conceptional age was 13/81 (16%) for indomethacin versus 23/94 (24%) for ibuprofen.
fi prova kurattiva klinika li kienet tinvolvi 175 tarbija mwielda qabel iż-żmien b’inqas minn 35 ġimgħa ta’ ġestazzjoni, l-inċidenza ta’ displażja bronkopulmonari fis-36 ġimgħa ta’ età ta’ wara l- konċepiment kienet ta’ 13/81 (16%) għal indomethacin kontra 23/94 (24%) għal ibuprofen.